vs
Side-by-side financial comparison of AVAX ONE TECHNOLOGY LTD. (AVX) and InMed Pharmaceuticals Inc. (INM). Click either name above to swap in a different company.
AVAX ONE TECHNOLOGY LTD. is the larger business by last-quarter revenue ($1.0M vs $820.2K, roughly 1.2× InMed Pharmaceuticals Inc.). InMed Pharmaceuticals Inc. runs the higher net margin — -247.3% vs -1633.6%, a 1386.3% gap on every dollar of revenue.
Teva Pharmaceutical Industries Ltd. is an Israeli multinational pharmaceutical company. Teva specializes primarily in generic drugs, but other business interests include branded-drugs, active pharmaceutical ingredients (APIs) and, to a lesser extent, contract manufacturing services and an out-licensing platform.
AVX vs INM — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $820.2K |
| Net Profit | $-16.6M | $-2.0M |
| Gross Margin | — | 22.5% |
| Operating Margin | -1522.1% | -247.3% |
| Net Margin | -1633.6% | -247.3% |
| Revenue YoY | — | -26.2% |
| Net Profit YoY | -480.2% | 21.2% |
| EPS (diluted) | $32.17 | $-0.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.0M | $820.2K | ||
| Q3 25 | $525.9K | $1.1M | ||
| Q2 25 | $452.0K | $1.3M | ||
| Q1 25 | $344.4K | $1.3M | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | $0 | $1.3M | ||
| Q2 24 | $41.3K | $1.3M | ||
| Q1 24 | — | $1.2M |
| Q4 25 | $-16.6M | $-2.0M | ||
| Q3 25 | $-8.4M | $-1.7M | ||
| Q2 25 | $-8.1M | $-1.8M | ||
| Q1 25 | $-145.5K | $-2.1M | ||
| Q4 24 | — | $-2.6M | ||
| Q3 24 | $-5.8M | $-1.7M | ||
| Q2 24 | $-4.2M | $-1.9M | ||
| Q1 24 | — | $-1.7M |
| Q4 25 | — | 22.5% | ||
| Q3 25 | — | 36.0% | ||
| Q2 25 | — | 44.2% | ||
| Q1 25 | 22.9% | 13.9% | ||
| Q4 24 | — | 41.5% | ||
| Q3 24 | — | 39.0% | ||
| Q2 24 | 18.4% | 36.3% | ||
| Q1 24 | — | 24.7% |
| Q4 25 | -1522.1% | -247.3% | ||
| Q3 25 | -496.6% | -154.2% | ||
| Q2 25 | -328.4% | -137.1% | ||
| Q1 25 | -600.0% | -168.1% | ||
| Q4 24 | — | -231.6% | ||
| Q3 24 | — | -132.7% | ||
| Q2 24 | -2827.7% | -150.5% | ||
| Q1 24 | — | -146.9% |
| Q4 25 | -1633.6% | -247.3% | ||
| Q3 25 | -1588.0% | -154.2% | ||
| Q2 25 | -1783.4% | -137.1% | ||
| Q1 25 | -42.2% | -168.1% | ||
| Q4 24 | — | -231.6% | ||
| Q3 24 | — | -132.7% | ||
| Q2 24 | -10243.5% | -151.0% | ||
| Q1 24 | — | -146.9% |
| Q4 25 | $32.17 | $-0.51 | ||
| Q3 25 | $-5.55 | $-0.44 | ||
| Q2 25 | $-27.60 | $-0.07 | ||
| Q1 25 | $-1.17 | $-1.94 | ||
| Q4 24 | — | $-3.64 | ||
| Q3 24 | $-57.19 | $-2.71 | ||
| Q2 24 | $-83.03 | $2.39 | ||
| Q1 24 | — | $-3.58 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $22.1M | $7.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $187.0M | $9.6M |
| Total Assets | $195.0M | $11.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $22.1M | $7.0M | ||
| Q3 25 | $894.7K | $9.4M | ||
| Q2 25 | $185.3K | $11.1M | ||
| Q1 25 | $1.4M | $4.7M | ||
| Q4 24 | — | $3.5M | ||
| Q3 24 | — | $5.6M | ||
| Q2 24 | — | $6.6M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | $1.8M | — | ||
| Q2 25 | $8.6M | — | ||
| Q1 25 | $10.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | — | ||
| Q2 24 | $3.1M | — | ||
| Q1 24 | — | — |
| Q4 25 | $187.0M | $9.6M | ||
| Q3 25 | $12.2M | $11.6M | ||
| Q2 25 | $4.1M | $13.4M | ||
| Q1 25 | $6.4M | $7.0M | ||
| Q4 24 | — | $6.2M | ||
| Q3 24 | $6.7M | $8.4M | ||
| Q2 24 | $11.3M | $9.2M | ||
| Q1 24 | — | $11.1M |
| Q4 25 | $195.0M | $11.2M | ||
| Q3 25 | $16.5M | $13.4M | ||
| Q2 25 | $15.2M | $15.6M | ||
| Q1 25 | $16.8M | $9.3M | ||
| Q4 24 | — | $8.5M | ||
| Q3 24 | $10.8M | $10.5M | ||
| Q2 24 | $15.7M | $11.8M | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | 0.15× | — | ||
| Q2 25 | 2.11× | — | ||
| Q1 25 | 1.59× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.33× | — | ||
| Q2 24 | 0.28× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-14.4M | $-2.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-14.4M | $-2.4M | ||
| Q3 25 | $-2.4M | $-1.6M | ||
| Q2 25 | $-884.1K | $-1.8M | ||
| Q1 25 | $-2.2M | $-1.7M | ||
| Q4 24 | — | $-2.5M | ||
| Q3 24 | $-1.2M | $-1.8M | ||
| Q2 24 | $-919.2K | $-1.0M | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -165.0% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
